Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7063746 | 0.86 | CYP2D6 (0.48) | CYP2D6 | |
| SCHEMBL13376616 | 0.80 | — | — | |
| SCHEMBL283339 | 0.79 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL5878869 | 0.79 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL283340 | 0.79 | CYP2D6 (0.44) | CYP2D6 | |
| SCHEMBL9647341 | 0.78 | PKM (0.40) | — | |
| SCHEMBL13456215 | 0.78 | — | — | |
| SCHEMBL24192869 | 0.77 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL11307910 | 0.77 | CYP2D6 (0.43) | CYP2D6 | |
| SCHEMBL20815509 | 0.77 | ADRB2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230088145-A1 | CYCLIC ORGANOSILICON COMPOUNDS AS ELECTRON DONORS IN ZEIGLER ?NATTA CATALYST SYSTEMS FOR PRODUCING PROPYLENE POLYMER HAVING HIGH MELT-FLOWABILITY | FORMOSA PLASTICS CORPORATION, U.S.A. | 2023-03-23 | — | — | US | disclosed |
| US-11572425-B2 | Cyclic organosilicon compounds as electron donors in Zeigler-Natta catalyst systems for producing propylene polymer having high melt-flowability | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210347785-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| CN-108003260-B | Cyclic organosilicon compounds as electron donors in ziegler-natta catalyst systems for the production of propylene polymers | 台塑美国公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20200277414-A1 | Cyclic Organosilicon Compounds as Electron Donors in Zeigler-Natta Catalyst Systems for Producing Propylene Polymer Having High Melt-Flowability | FORMOSA PLASTICS CORPORATION, U.S.A. | 2020-09-03 | — | — | US | disclosed |
| US-10654947-B2 | Cyclic organosilicon compounds as electron donors in Zeigler-Natta catalyst systems for producing propylene polymer having high melt-flowability | FORMOSA PLASTICS CORPORATION, USA (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| CN-108003260-A | It is used as the cyclic organosilicon compounds of electron donor in the ziegler-natta catalyst systems for producing acrylic polymers | 台塑美国公司 | 2018-05-08 | — | — | CN | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2000489-A9 | CURABLE AQUEOUS COMPOSITION | Kansai Paint Co., Ltd. (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-2000489-A2 | CURABLE AQUEOUS COMPOSITION | Kansai Paint Co., Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | KANSAI PAINT CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| EP-1798218-A1 | MONOMER COMPOUND, PROCESS FOR PRODUCING THE SAME, POLYMER THEREOF, AND WATER-BASED CURABLE COMPOSITION | KANSAI PAINT CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2003019383-A1 | CRYSTALLINE ALUMINOPHOSPHATE PRODUCTION PROCESS AND CRYSTALLINE ALUMINOPHOSPHATE | SHOWA DENKO KK (JP) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | CYP2D6 623/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | CYP2D6 4807/4885 |
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | THEM6, PAM, WEE1 | CYP2D6 1999/4885 |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | NR5A2, NR5A1, NR4A1 | CYP2D6 90/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | CYP2D6 968/4885 |
| US-20210347785-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | CD274, PDCD1, PDCD1LG2 | CYP2D6 1271/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CYP2D6 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.